The stock of PTC Therapeutics, Inc. (NASDAQ:PTCT) is a huge mover today! About 853,692 shares traded hands. PTC Therapeutics, Inc. (NASDAQ:PTCT) has declined 11.93% since April 8, 2016 and is downtrending. It has underperformed by 17.58% the S&P500.
The move comes after 6 months positive chart setup for the $227.13 million company. It was reported on Nov, 10 by Barchart.com. We have $8.51 PT which if reached, will make NASDAQ:PTCT worth $86.31M more.
Analysts await PTC Therapeutics, Inc. (NASDAQ:PTCT) to report earnings on November, 14. They expect $-1.19 EPS, up 6.30% or $0.08 from last year’s $-1.27 per share. After $-1.14 actual EPS reported by PTC Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 4.39% negative EPS growth.
PTC Therapeutics, Inc. (NASDAQ:PTCT) Ratings Coverage
Out of 7 analysts covering PTC Therapeutics (NASDAQ:PTCT), 2 rate it a “Buy”, 0 “Sell”, while 5 “Hold”. This means 29% are positive. PTC Therapeutics has been the topic of 16 analyst reports since July 31, 2015 according to StockzIntelligence Inc. The stock of PTC Therapeutics, Inc. (NASDAQ:PTCT) earned “Underperform” rating by Jefferies on Wednesday, November 25. RBC Capital Markets maintained PTC Therapeutics, Inc. (NASDAQ:PTCT) on Friday, July 31 with “Outperform” rating. JP Morgan downgraded the stock to “Neutral” rating in Tuesday, February 23 report. Jefferies initiated PTC Therapeutics, Inc. (NASDAQ:PTCT) on Friday, October 23 with “Hold” rating. On Wednesday, February 24 the stock rating was upgraded by Jefferies to “Hold”. As per Wednesday, February 24, the company rating was maintained by Wedbush. The company was downgraded on Wednesday, February 24 by RBC Capital Markets. Citigroup downgraded the stock to “Neutral” rating in Wednesday, February 24 report. The firm has “Buy” rating given on Tuesday, August 25 by Citigroup. The rating was maintained by Oppenheimer on Friday, October 16 with “Outperform”.
According to Zacks Investment Research, “PTC Therapeutics, Inc. is a biopharmaceutical company. It is focused on the discovery and development of orally administered, small-molecule drugs for genetic disorders, oncology and infectious disease. PTC Therapeutics, Inc. is based in South Plainfield, United States.”
Insitutional Activity: The institutional sentiment increased to 1.23 in Q2 2016. Its up 0.40, from 0.83 in 2016Q1. The ratio increased, as 17 funds sold all PTC Therapeutics, Inc. shares owned while 30 reduced positions. 17 funds bought stakes while 41 increased positions. They now own 28.13 million shares or 3.23% less from 29.06 million shares in 2016Q1.
Teachers reported 52,338 shares or 0% of all its holdings. Blackrock Gp Limited has 202,283 shares for 0% of their US portfolio. Moreover, Wells Fargo Mn has 0% invested in PTC Therapeutics, Inc. (NASDAQ:PTCT) for 29,687 shares. Northern Tru Corp accumulated 0% or 456,607 shares. Bank & Trust Of New York Mellon last reported 150,068 shares in the company. Voya Inv Mgmt Ltd has invested 0% of its portfolio in PTC Therapeutics, Inc. (NASDAQ:PTCT). Ubs Asset Mngmt Americas Incorporated holds 0% or 615,531 shares in its portfolio. Manufacturers Life The holds 0% or 37,171 shares in its portfolio. Jane Street Grp Ltd Liability Corp has 13,669 shares for 0% of their US portfolio. The New Jersey-based Blackrock Lc has invested 0% in PTC Therapeutics, Inc. (NASDAQ:PTCT). Moreover, Pictet Asset Mngmt Ltd has 0.04% invested in PTC Therapeutics, Inc. (NASDAQ:PTCT) for 1.33 million shares. Sei Investments Communication accumulated 29,081 shares or 0% of the stock. Frontier Capital Mgmt Ltd Liability Corp has 1.43M shares for 0.08% of their US portfolio. Commerzbank Aktiengesellschaft Fi accumulated 22,488 shares or 0% of the stock. Cornerstone Advisors accumulated 100 shares or 0% of the stock.
More recent PTC Therapeutics, Inc. (NASDAQ:PTCT) news were published by: Fool.com which released: “Why PTC Therapeutics, Inc. Is Crashing Today” on October 17, 2016. Also Prnewswire.com published the news titled: “PTC Therapeutics to Host Conference Call to Discuss Third Quarter Financial …” on October 19, 2016. Marketwatch.com‘s news article titled: “PTC Therapeutics stock plummets 29% after FDA denies company’s DMD drug appeal” with publication date: October 17, 2016 was also an interesting one.
PTCT Company Profile
PTC Therapeutics, Inc., incorporated on March 31, 1998, is a biopharmaceutical firm focused on the discovery, development and commercialization of orally administered, small molecule therapeutics that focus on post-transcriptional control processes. The Company’s internally discovered pipeline addresses multiple therapeutic areas, including rare disorders, oncology and infectious diseases. The Company’s lead product, Translarna (ataluren), is used for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in ambulatory patients with age of over five years and older in over 30 member states of the European Economic Area (EEA). It holds commercialization rights to Translarna for all indications in all territories, across the world. Translarna is designated as an orphan medicinal product for the treatment of cystic fibrosis (CF), duchenne muscular dystrophy (DMD), Mucopolysaccharidosis type I (MPS I), and aniridia. The Company’s programs include Translarna for nmDMD, Translarna for nonsense mutation cystic fibrosis (nmCF), Translarna for mucopolysaccharidosis type I caused by nonsense mutation (nmMPS I), Translarna for nonsense mutation aniridia, Translarna for nonsense mutation Dravet syndrome/CDKL5, Spinal muscular atrophy (SMA) collaboration with Spinal Muscular Atrophy Foundation (SMA Foundation) and F. Hoffman-La Roche Ltd and Hoffman- La Roche Inc. (collectively Roche), and Cancer stem cell program (PTC596).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.